Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Administration of tocilizumab to patients with high concentrations of IL-6 in the course of COVID-19 is associated with a better prognosis

Robert Flisiak, Jerzy Jaroszewicz, Magdalena Rogalska, Tadeusz Łapiński, Aleksandra Berkan-Kawińska, Beata Bolewska, Magdalena Tudrujek-Zdunek, Dorota Kozielewicz, Marta Rorat, Piotr Leszczyński, Krzysztof Kłos, Justyna Kowalska, Paweł Pabjan, Anna Piekarska, Iwona Mozer-Lisewska, Krzysztof Tomasiewicz, Małgorzata Pawłowska, Krzysztof Simon, Joanna Polańska, Dorota Zarębska-Michaluk
doi: https://doi.org/10.1101/2021.01.28.21249932
Robert Flisiak
1Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: robert.flisiak1@gmail.com
Jerzy Jaroszewicz
2Department of Infectious Diseases and Hepatology, Medical University of Silesia, Katowice, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Magdalena Rogalska
1Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tadeusz Łapiński
1Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aleksandra Berkan-Kawińska
3Department of Infectious Diseases and Hepatology, Medical University of Łódź, Łódź, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beata Bolewska
4Department of Infectious Diseases, University of Medical Sciences, Poznań, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Magdalena Tudrujek-Zdunek
5Department of Infectious Diseases and Hepatology, Medical University of Lublin, Lublin, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dorota Kozielewicz
6Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marta Rorat
7Department of Forensic Medicine, Wrocław Medical University, Wrocław, Poland
8First Infectious Diseases Ward, Gromkowski Regional Specialist Hospital in Wrocław, Wrocław, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Piotr Leszczyński
9Department of Rheumatology, Rehabilitation and Internal Medicine, Poznan University of Medical Sciences
10Department of Rheumatology and Osteoporosis, Szpital im. J. Strusia w Poznaniu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Krzysztof Kłos
11Department of Infectious Diseases and Allergology, Military Institute of Medicine, Warsaw, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Justyna Kowalska
12Department of Adults’ Infectious Diseases, Medical University of Warsaw, Warsaw, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paweł Pabjan
13Department of Infectious Diseases, Jan Kochanowski University, Kielce, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Piekarska
3Department of Infectious Diseases and Hepatology, Medical University of Łódź, Łódź, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Iwona Mozer-Lisewska
4Department of Infectious Diseases, University of Medical Sciences, Poznań, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Krzysztof Tomasiewicz
5Department of Infectious Diseases and Hepatology, Medical University of Lublin, Lublin, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Małgorzata Pawłowska
6Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Krzysztof Simon
14Department of Infectious Diseases and Hepatology, Wrocław Medical University, Wrocław, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joanna Polańska
15Department of Data Science and Engineering, Silesian University of Technology, Gliwice, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dorota Zarębska-Michaluk
13Department of Infectious Diseases, Jan Kochanowski University, Kielce, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Summary

Background Despite the direct viral activity, the pathogenesis of coronavirus disease 2019 (COVID-19) includes an overproduction of cytokines including interleukin 6 (IL-6). Therefore tocilizumab (TCZ), a monoclonal antibody against IL-6 receptors, became considered as a possible therapeutic option.

Methods Patients were selected from the SARSTer national database, which included 2332 individuals with COVID-19 and the current study included 825 adult patients with moderate to severe course. The retrospective analysis was performed in 170 patients treated with TCZ and 655 without this medication or any other anti-cytokine therapy. The end-points of treatment effectiveness were a rate of death, need for mechanical ventilation, and clinical improvement.

Results Patients treated with TCZ were balanced compared to non-TCZ regarding gender, age, BMI, and prevalence of coexisting conditions. The reduced death rate was demonstrated in patients treated with TCZ and baseline IL-6 >100 pg/ml (hazard ratio [HR]: 0.27, 95% confidence interval [CI]:0.10-0.78), or those needing oxygen supplementations who worsened within 7 days of hospitalization (HR: 0.38, 95% CI:0.16-0.88). The best effectiveness of TCZ was achieved in patients with a combination of baseline IL-6>100 pg/ml and either SpO2≤90% (HR for death, mechanical ventilation, and clinical improvement after 21 or 28 days: 0.07, 0.14, 5.53, 5.18 respectively) or requiring oxygen supplementation (HR for death and clinical improvement after 21 or 28 days, 0.18, 2.66, 2.85 respectively).

Conclusions Tocilizumab administered for COVID-19 in patients with a baseline concentration of IL-6>100 pg/ml is associated with reduced mortality and faster clinical improvement, particularly if there is a need for oxygen supplementation due to SpO2≤90%.

Competing Interest Statement

RF reports grants from Abbvie, Gilead, Merck, personal fees from Gilead, Abbvie, Merck, Roche, and non-financial support from Abbvie, Gilead, and Merck outside the submitted work. DZM, PP reports personal fees from Gilead and Abbvie, outside the submitted work. JJ reports personal fees from Gilead, Abbvie, Bausch Health, Merck, Promed, Roche, and non-financial support from Abbvie, Gilead, and Merck outside the submitted work. KS reports personal fees from Gilead, Abbvie, Merck, outside the submitted work KT reports personal fees from Gilead, Abbvie, Merck, Promed, Roche, and non-financial support from Abbvie, Gilead, and Merck outside the submitted work. JK reports personal fees from Gilead, Merck, ViiV, Janssen outside the submitted work. IML reports personal fees from Gilead, Abbvie and Pfizer ABK, JP, BB, KK, MP, AP, DK, MTZ, CI, MRog, MRor declare no competing interests.

Funding Statement

SARSTer study is supported by the Polish Association of Epidemiologists and Infectiologists and Medica Research Agency

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study received the approval of the Ethics Committee of the Medical University of Białystok. Local ethics committees approved use of tocilizumab as an experimental therapy

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Ethics Committee: The study received the approval of the Ethics Committee of the Medical University of Białystok.

  • Conflict of interest: RF reports grants from Abbvie, Gilead, Merck, personal fees from Gilead, Abbvie, Merck, Roche, and non-financial support from Abbvie, Gilead, and Merck outside the submitted work.

    DZM, PP reports personal fees from Gilead and Abbvie, outside the submitted work.

    JJ reports personal fees from Gilead, Abbvie, Bausch Health, Merck, Promed, Roche, and non-financial support from Abbvie, Gilead, and Merck outside the submitted work.

    KS reports personal fees from Gilead, Abbvie, Merck, outside the submitted work

    KT reports personal fees from Gilead, Abbvie, Merck, Promed, Roche, and non-financial support from Abbvie, Gilead, and Merck outside the submitted work.

    JK reports personal fees from Gilead, Merck, ViiV, Janssen outside the submitted work. IML reports personal fees from Gilead, Abbvie and Pfizer

    ABK, JP, BB, KK, MP, AP, DK, MTZ, CI, MRog, MRor declare no competing interests.

Data Availability

data will be available upon request from the first/corresponding author

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted February 01, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Administration of tocilizumab to patients with high concentrations of IL-6 in the course of COVID-19 is associated with a better prognosis
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Administration of tocilizumab to patients with high concentrations of IL-6 in the course of COVID-19 is associated with a better prognosis
Robert Flisiak, Jerzy Jaroszewicz, Magdalena Rogalska, Tadeusz Łapiński, Aleksandra Berkan-Kawińska, Beata Bolewska, Magdalena Tudrujek-Zdunek, Dorota Kozielewicz, Marta Rorat, Piotr Leszczyński, Krzysztof Kłos, Justyna Kowalska, Paweł Pabjan, Anna Piekarska, Iwona Mozer-Lisewska, Krzysztof Tomasiewicz, Małgorzata Pawłowska, Krzysztof Simon, Joanna Polańska, Dorota Zarębska-Michaluk
medRxiv 2021.01.28.21249932; doi: https://doi.org/10.1101/2021.01.28.21249932
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Administration of tocilizumab to patients with high concentrations of IL-6 in the course of COVID-19 is associated with a better prognosis
Robert Flisiak, Jerzy Jaroszewicz, Magdalena Rogalska, Tadeusz Łapiński, Aleksandra Berkan-Kawińska, Beata Bolewska, Magdalena Tudrujek-Zdunek, Dorota Kozielewicz, Marta Rorat, Piotr Leszczyński, Krzysztof Kłos, Justyna Kowalska, Paweł Pabjan, Anna Piekarska, Iwona Mozer-Lisewska, Krzysztof Tomasiewicz, Małgorzata Pawłowska, Krzysztof Simon, Joanna Polańska, Dorota Zarębska-Michaluk
medRxiv 2021.01.28.21249932; doi: https://doi.org/10.1101/2021.01.28.21249932

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (166)
  • Anesthesia (49)
  • Cardiovascular Medicine (447)
  • Dentistry and Oral Medicine (80)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (188)
  • Epidemiology (5196)
  • Forensic Medicine (3)
  • Gastroenterology (192)
  • Genetic and Genomic Medicine (746)
  • Geriatric Medicine (76)
  • Health Economics (210)
  • Health Informatics (689)
  • Health Policy (350)
  • Health Systems and Quality Improvement (221)
  • Hematology (98)
  • HIV/AIDS (161)
  • Infectious Diseases (except HIV/AIDS) (5788)
  • Intensive Care and Critical Care Medicine (353)
  • Medical Education (101)
  • Medical Ethics (25)
  • Nephrology (80)
  • Neurology (754)
  • Nursing (43)
  • Nutrition (129)
  • Obstetrics and Gynecology (140)
  • Occupational and Environmental Health (230)
  • Oncology (473)
  • Ophthalmology (149)
  • Orthopedics (37)
  • Otolaryngology (93)
  • Pain Medicine (39)
  • Palliative Medicine (19)
  • Pathology (138)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (135)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (851)
  • Public and Global Health (1983)
  • Radiology and Imaging (340)
  • Rehabilitation Medicine and Physical Therapy (154)
  • Respiratory Medicine (282)
  • Rheumatology (93)
  • Sexual and Reproductive Health (72)
  • Sports Medicine (74)
  • Surgery (107)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)